Guggenheim says Calliditas' kidney disease drug likely to get full US approval; shares rise

Calliditas Therapeutics AB

06/11/2023 11:54

** U.S.-listed shares of Swedish drug developer Calliditas
Therapeutics AB  CALTX.ST  rise 1.9% to $16.51 premarket
    ** Guggenheim says CALT's kidney disease drug Tarpeyo is
likely to receive full U.S. approval next month
    ** Tarpeyo currently has U.S. FDA's accelerated approval
    ** Up to last close, shares down 4.7% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))